Impact of CT attenuation correction on viable myocardium detection in combined SPECT and PET/CT: A retrospective cohort study
Fukai Zhao,Yue Chen,Jiaming Zhao,Zekun Pang,Jiao Wang,Bing Cao,Jianming Li
DOI: https://doi.org/10.1097/md.0000000000040175
IF: 1.6
2024-10-30
Medicine
Abstract:The combination of Technetium-99m-methoxyisobutylisonitrile (Tc-99m-MIBI) single-photon emission computed tomography (SPECT) and Fluorine-18-fluorodeoxyglucose (F-18-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for myocardial perfusion/metabolic imaging is commonly used to assess myocardial viability, guide treatment strategies, and predict outcomes in patients with ischemic heart failure. [ 1 , 2 ] Hibernating myocardium (HM) is a chronic and potentially reversible myocardial dysfunction caused by ischemia. In myocardial viability imaging, perfusion-metabolism mismatch is considered a characteristic feature of HM, whereas a decrease or lack of perfusion/metabolism match indicates the presence of infarct scar tissue. [ 3 , 4 ] Research evidence suggests that the extent of functional improvement in the heart after revascularization is positively correlated with the proportion of hibernating myocardium. [ 5 ] Hence, the presence and proportion of HM and scars are critical for determining the suitability for revascularization, where more HM and fewer scars correlate with a better potential for recovery and prognosis. Therefore, an accurate assessment of HM and scars is crucial for clinical decision-making. Clinical studies [ 6 ] have shown that timely coronary revascularization to restore blood flow to the HM can improve the symptoms and prognosis of patients with ischemic heart failure. While PET/CT myocardial perfusion imaging (MPI) generally provides high-quality imaging with reduced impact from soft tissue attenuation, making it ideal for evaluating myocardial blood flow, it is not entirely free from attenuation effects. Moreover, its widespread clinical application is limited by factors such as the availability of PET/CT facilities, accessibility, and the cost of positron-emitting radiopharmaceuticals. Consequently, most clinical practice studies [ 7–9 ] have employed SPECT MPI. However, SPECT MPI is known to suffer from attenuation artifacts caused by uneven absorption of low-energy gamma photons by the breast, diaphragm, and chest wall muscles, which can lead to false positives or exacerbate perceived reductions in perfusion. [ 10 , 11 ] Our search revealed that some large-scale multicenter clinical studies, such as the STICH trial, [ 12 ] used SPECT MPI without combining it with PET/CT metabolic imaging or applying attenuation correction (AC). Furthermore, recent studies [ 8 , 13–18 ] assessing myocardial viability using SPECT MPI combined with F-18-FDG PET/CT did not analyze AC-corrected SPECT data. In patients with ischemic heart failure, the enlarged heart could further exacerbate the range and severity of attenuation artifacts, potentially leading to greater misestimation of perfusion deficits, which could, in turn, affect the calculation results of HM, Scar, and other normal myocardial areas when combined with PET/CT metabolic imaging, thereby affecting the accuracy of myocardial viability and type calculations.
medicine, general & internal